公开(公告)号：US20060205637A1

公开(公告)日：2006-09-14

申请号：US10522268

申请日：2003-07-18

申请人： Alma Dal Pozzo ,  Giuseppe Giannini ,  Claudio Pisano

发明人： Alma Dal Pozzo ,  Giuseppe Giannini ,  Claudio Pisano

IPC分类号： A61K38/12 ,  C07K5/12

CPC分类号： C07K7/54 ,  A61K38/00 ,  C07K7/64

摘要： Compounds of formula (I) cyclo [NX1-R1-CO—NX2-R2-CO—NX3-R3-CO—NX4-CO—NX5-R5-CO], wherein at least one x-fluoroalkylated amino acid is present, are inhibitors of integrins, particularly those belonging to the alphavbeta3 and alphavbeta5 family, and thus are useful as medicaments, particularly for the treatment of the underlying diseases responsible for abnormal angiogenesis, such as retinopathy, acute kidney failure, osteoporosis and metastases. The compounds described herein are also useful as diagnostic agents, when appropriately labelled, especially for the detection and location of small tumour masses and arterial occlusion events.

摘要翻译： 式（I）环[NX1-R1-CO-NX2-R2-CO-NX3-R3-CO-NX4-CO-NX5-R5-CO]的化合物，其中存在至少一个x-氟烷基化氨基酸 整合素的抑制剂，特别是属于alphavbeta3和alphavbeta5家族的那些，因此可用作药物，特别是用于治疗负责异常血管生成的潜在疾病，例如视网膜病变，急性肾功能衰竭，骨质疏松症和转移。 当适当标记时，本文所述的化合物还可用作诊断剂，特别是用于小肿瘤块和动脉闭塞事件的检测和定位。

公开(公告)号：US08975248B2

公开(公告)日：2015-03-10

申请号：US11720776

申请日：2005-12-13

申请人： Sara Zaknoen ,  Margaret Ma Woo ,  Richard William Versace ,  Claudio Pisano ,  Loredana Vesci

发明人： Sara Zaknoen ,  Margaret Ma Woo ,  Richard William Versace ,  Claudio Pisano ,  Loredana Vesci

IPC分类号： A61K31/47 ,  A61K31/282 ,  A61K33/24 ,  A61K39/395 ,  A61K31/427 ,  A61K31/53 ,  A61K31/555 ,  A61K31/4745 ,  A61K31/337 ,  A61K45/06

CPC分类号： A61K45/06 ,  A61K31/282 ,  A61K31/337 ,  A61K31/427 ,  A61K31/4745 ,  A61K31/53 ,  A61K31/555 ,  A61K33/24 ,  A61K39/395 ,  A61K2300/00

摘要： A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.

摘要翻译： 公开了用于治疗患有与持续血管发生相关的增殖性疾病或疾病的患者的联合疗法。 用喜树碱衍生物和一种或多种选自微管活性剂的化学治疗剂治疗患者; 烷基化剂; 抗肿瘤抗代谢物; 铂化合物; 拓扑异构酶II抑制剂; VEGF抑制剂; 酪氨酸激酶抑制剂; EGFR激酶抑制剂; mTOR激酶抑制剂; 胰岛素样生长因子I抑制剂; Raf激酶抑制剂; 单克隆抗体; 蛋白酶体抑制剂; HDAC抑制剂; 和电离辐射。

公开(公告)号：US20120093809A1

公开(公告)日：2012-04-19

申请号：US13256531

申请日：2009-12-01

申请人： Claudio Cavazza ,  Giulia Tagliafico ,  Paolo Carminati ,  Gabriella Singrossi ,  Silvia Carminati ,  Giuseppe Paolo Carminati ,  Claudio Pisano

发明人： Claudio Cavazza ,  Giulia Tagliafico ,  Paolo Carminati ,  Gabriella Singrossi ,  Silvia Carminati ,  Giuseppe Paolo Carminati ,  Claudio Pisano

IPC分类号： A61K31/205 ,  A61K31/282 ,  A61P35/02 ,  A61K31/704 ,  A61P35/00 ,  A61K39/395 ,  A61K33/24

CPC分类号： A61K45/06 ,  A61K31/205 ,  A61K31/282 ,  A61K31/337 ,  A61K31/427 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/513 ,  A61K31/555 ,  A61K38/14 ,  A61K2300/00

摘要： The present invention relates to the use of an alkanoyl L-carnitine selected from the group consisting of acetyl, propionyl, valeryl, isovaleryl and butirryl L-carnitine; in combination with one or more chemotherapeutic agent selected from the group consisting of: a camptothecin derivative; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; toxins; and imides; for the treatment of neoplasms.

摘要翻译： 本发明涉及选自乙酰基，丙酰基，戊酰基，异戊酰基和丁基L-肉毒碱的烷酰基L-肉毒碱的用途; 与一种或多种选自以下的化学治疗剂组合：喜树碱衍生物; 烷基化剂; 抗肿瘤抗代谢物; 铂化合物; 拓扑异构酶抑制剂; VEGF抑制剂; 酪氨酸激酶抑制剂; EGFR激酶抑制剂; mTOR激酶抑制剂; 胰岛素样生长因子I抑制剂; Raf激酶抑制剂; 单克隆抗体; 蛋白酶体抑制剂; HDAC抑制剂; 毒素 和imides; 用于治疗肿瘤。

公开(公告)号：US20100028338A1

公开(公告)日：2010-02-04

申请号：US11720776

申请日：2005-12-13

申请人： Sara Zaknoen ,  Margaret Ma Woo ,  Richard William Versace ,  Claudio Pisano ,  Loredana Vesci

发明人： Sara Zaknoen ,  Margaret Ma Woo ,  Richard William Versace ,  Claudio Pisano ,  Loredana Vesci

IPC分类号： A61K39/395 ,  A61K31/437 ,  A61K31/505 ,  A61K31/7068 ,  A61K33/24 ,  A61K31/704 ,  A61K31/496 ,  A61P35/00 ,  A61K31/69

CPC分类号： A61K45/06 ,  A61K31/282 ,  A61K31/337 ,  A61K31/427 ,  A61K31/4745 ,  A61K31/53 ,  A61K31/555 ,  A61K33/24 ,  A61K39/395 ,  A61K2300/00

摘要： A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.

摘要翻译： 公开了用于治疗患有与持续血管发生相关的增殖性疾病或疾病的患者的联合疗法。 用喜树碱衍生物和一种或多种选自微管活性剂的化学治疗剂治疗患者; 烷基化剂; 抗肿瘤抗代谢物; 铂化合物; 拓扑异构酶II抑制剂; VEGF抑制剂; 酪氨酸激酶抑制剂; EGFR激酶抑制剂; mTOR激酶抑制剂; 胰岛素样生长因子I抑制剂; Raf激酶抑制剂; 单克隆抗体; 蛋白酶体抑制剂; HDAC抑制剂; 和电离辐射。

公开(公告)号：US20050131060A1

公开(公告)日：2005-06-16

申请号：US10965740

申请日：2004-10-18

申请人： Claudio Pisano ,  Teresa Riccioni

发明人： Claudio Pisano ,  Teresa Riccioni

IPC分类号： C07D493/10 ,  A61K31/203 ,  A61K31/365 ,  A61K45/00 ,  A61K45/06 ,  A61P3/10 ,  A61P5/50 ,  A61P7/00 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00

CPC分类号： A61K45/06 ,  A61K31/365 ,  A61K31/20 ,  A61K2300/00

摘要： This invention features the use of the spirolaxine of formula (I) for the treatment of those pathologies responding to the activation of the PPARγ receptor, such as the Type 2 insulin-resistant diabetes. This invention also features a pharmaceutical composition in which the spirolaxine of formula (I) acts as active principle in association with the all-trans retinoic acid of formula (II) for the treatment of those pathologies responding to the activation of the PPARγ receptor, such as the acute malignant haemopathies.

摘要翻译： 本发明的特征在于式（I）的斯曲拉西治疗对PPARγ受体的激活作用的那些病理学的应用，例如2型胰岛素抵抗性糖尿病。 本发明还特征在于一种药物组合物，其中式（I）的旋风司他作为与式（II）的全反式维甲酸结合的活性成分，用于治疗对PPARγ受体的激活作出反应的那些病理学， 作为急性恶性血液病。

公开(公告)号：US20100330200A1

公开(公告)日：2010-12-30

申请号：US12517926

申请日：2007-12-11

申请人： Paolo Carminati ,  Claudio Pisano ,  Loredana Vesci ,  Franco Zunino

发明人： Paolo Carminati ,  Claudio Pisano ,  Loredana Vesci ,  Franco Zunino

IPC分类号： A61K33/24 ,  A61P35/00 ,  A61P35/04

CPC分类号： A61K33/24 ,  A61K31/192 ,  A61K31/282 ,  A61K45/06 ,  A61K2300/00

摘要： A combination comprising an atypical retinoid compound, preferably E-4-(3-(1-adamantyl)-4-hydroxyphenyl)cinnamic acid and an anticancer drug of the platinum family, preferably cisuplatin, together with a pharmaceutical composition comprising it and a kit for its administration in unitary or in coordinated sequential form. The kit preferably comprises a first formulation of E-4-(3-(1-adamantyl)-4-hydroxyphenyl)cinnamic acid dissolved in a mixture of ethanol and cremophor, and susupended in a saline solution, and a second formulation of cisuplatin in saline solution. The combination is used for the preparation of a medicament to inhibit tumor growth and tumor migration, in particular for the treatment of ovarian tumor and/or carcinoma.

摘要翻译： 包含非典型类视色素化合物，优选E-4-（3-（1-金刚烷基）-4-羟基苯基）肉桂酸和铂族的抗癌药物，优选顺铂，以及包含它的药物组合物和试剂盒 以统一或协调的顺序形式进行管理。 试剂盒优选包含溶解在乙醇和Cremophor的混合物中并在盐溶液中混悬的E-4-（3-（1-金刚烷基）-4-羟基苯基）肉桂酸的第一配方，并且将顺铂的第二制剂 生理盐水。 该组合用于制备抑制肿瘤生长和肿瘤迁移的药物，特别是用于治疗卵巢肿瘤和/或癌。

公开(公告)号：US20060183798A1

公开(公告)日：2006-08-17

申请号：US11402961

申请日：2006-04-13

申请人： Claudio Cavazza ,  Claudio Pisano ,  Loredana Vesci

发明人： Claudio Cavazza ,  Claudio Pisano ,  Loredana Vesci

IPC分类号： A61K31/22 ,  A61K31/426 ,  A61K31/337 ,  A61K31/4745 ,  A61K33/24 ,  A61K31/28

CPC分类号： A61K31/22 ,  A61K31/205 ,  A61K31/221 ,  A61K31/28 ,  A61K31/335 ,  A61K31/337 ,  A61K31/426 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/555 ,  A61K33/24 ,  A61K38/14 ,  A61K45/06 ,  A61K2300/00

摘要： A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compounds, taxanes, epothilone class, vinca alkaloids, said method comprising the administration in a co-ordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said peripheral neuropathies, an effective amount of acetyl L-carnitine or of a pharmaceutically acceptable salt thereof. In case of prevention, acetyl L-carnitine is administered to a subject, in view of the need of a treatment with an anticancer agent, immediately before or immediately after surgical removal of the tumor, but in any case before the administration of the anticancer agent. Acetyl L-carnitine can enhance the supportive effect of physiological NGF during chemotherapy-induced neuropathy, thus avoiding the problem of the local and general side effects of the exogenous administration of NGF which are a major problem of this neuroprotective strategy.

公开(公告)号：US06610699B2

公开(公告)日：2003-08-26

申请号：US09769488

申请日：2001-01-26

申请人： Claudio Cavazza ,  Claudio Pisano ,  Loredana Vesci

发明人： Claudio Cavazza ,  Claudio Pisano ,  Loredana Vesci

IPC分类号： A61K3144

CPC分类号： A61K45/06 ,  A61K31/205 ,  A61K31/221 ,  A61K31/28 ,  A61K31/335 ,  A61K31/475 ,  A61K31/555 ,  A61K33/24 ,  A61K38/14 ,  A61K2300/00

摘要： Alkanoyl L-carnitines of the formula: where R is hydrogen or a C2-8 alkanoyl group and X− is an anion of a pharmaceutically acceptable salt, are used in conjunction with anticancer agents such as taxol or bleomycin to improve the therapeutic index and reduce side effects typical of anticancer chemotherapy.

摘要翻译： 其中R为氢或C2-8烷酰基，X为药学上可接受的盐的阴离子的烷酰基L-肉碱与抗癌剂如紫杉醇或博来霉素结合使用，以改善治疗指数并减少 抗癌化疗典型的副作用。

公开(公告)号：US08853233B2

公开(公告)日：2014-10-07

申请号：US12526225

申请日：2008-02-07

申请人： Claudio Pisano ,  Loredana Vesci ,  Franco Zunino

发明人： Claudio Pisano ,  Loredana Vesci ,  Franco Zunino

IPC分类号： A61K31/4745

CPC分类号： A61K31/4745

摘要： A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.

摘要翻译： 喜树碱衍生物的亚类被公开用于制备用于治疗选自头颈癌，胰腺癌，黑素瘤，膀胱癌，间皮瘤和表皮样皮肤癌的癌症或肿瘤病理学的药物。

公开(公告)号：US08829021B2

公开(公告)日：2014-09-09

申请号：US12669134

申请日：2008-07-03

申请人： Claudio Pisano ,  Loredana Vesci ,  Paolo Carminati

发明人： Claudio Pisano ,  Loredana Vesci ,  Paolo Carminati

IPC分类号： A61K31/4375 ,  A61P35/00 ,  C07D457/14 ,  A61K31/4745

CPC分类号： A61K31/4745

摘要： A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of pediatric tumors such as for examplerhabdomyosarcoma, primitive neuroectodermal tumors (PNET) and neuroblastoma.

摘要翻译： 喜树碱衍生物的亚类被公开用于制备用于治疗儿科肿瘤的药物，例如用于示例性腹膜肉瘤，原始神经外胚层肿瘤（PNET）和神经母细胞瘤。